154 related articles for article (PubMed ID: 19697098)
1. Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
Yamauchi T; Mori Y; Miyamoto T; Kamezaki K; Aoki T; Yamamoto A; Takenaka K; Iwasaki H; Harada N; Nagafuji K; Teshima T; Akashi K
Int J Hematol; 2009 Oct; 90(3):416-420. PubMed ID: 19697098
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M; Illmer T; Oelschlaegel U; Schetelig J; Ordemann R; Schaich M; Hänel M; Schuler U; Thiede C; Kiani A; Platzbecker U; Ehninger G
Clin Cancer Res; 2008 Sep; 14(17):5585-93. PubMed ID: 18765552
[TBL] [Abstract][Full Text] [Related]
5. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
Sakamaki H
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
[TBL] [Abstract][Full Text] [Related]
6. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
Sumiyoshi R; Tashiro H; Saito S; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2020 Aug; 99(35):e22064. PubMed ID: 32871966
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Zwaan CM; Reinhardt D; Corbacioglu S; van Wering ER; Bökkerink JP; Tissing WJ; Samuelsson U; Feingold J; Creutzig U; Kaspers GJ
Blood; 2003 May; 101(10):3868-71. PubMed ID: 12543868
[TBL] [Abstract][Full Text] [Related]
11. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
Ando T; Mitani N; Matsunaga K; Nakazora T; Gondo T; Yujiri T; Tanizawa Y
Tohoku J Exp Med; 2010 Feb; 220(2):121-6. PubMed ID: 20139663
[TBL] [Abstract][Full Text] [Related]
14. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H
Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520
[TBL] [Abstract][Full Text] [Related]
16. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.
Eom KS; Kim HJ; Cho BS; Choi SM; Lee DG; Lee SE; Yahng SA; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Park CW; Min WS
Leuk Lymphoma; 2011 Dec; 52(12):2321-8. PubMed ID: 22023488
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
Takeshita A
Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
[TBL] [Abstract][Full Text] [Related]
20. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
